COAG Hemab Therapeutics Holdings, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2114044 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3.0%
Debt / equity0.00x
Current ratio33.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $24.64M | $20.34M | $19.46M | $14.55M | $12.87M | $14.10M |
| SG&A expense | $5.12M | $5.74M | $4.15M | $2.50M | $3.18M | $2.46M |
| Operating income | -$29.76M | -$26.08M | -$23.61M | -$17.05M | -$16.06M | -$16.56M |
| Pretax income | -$26.61M | -$24.05M | -$22.68M | -$16.97M | -$12.21M | -$15.50M |
| Income tax | $693,000 | $97,000 | $12,000 | $98,000 | $4,000 | -$190,000 |
| Net income | -$27.30M | -$24.15M | -$22.69M | -$17.07M | -$12.21M | -$15.31M |
| EBITDA | -$29.68M | -$26.00M | -$23.54M | -$16.98M | -$15.98M | -$16.48M |
| EPS (basic) | -0.58 | -0.80 | -23.98 | -18.04 | -12.91 | -16.18 |
| EPS (diluted) | -0.58 | -0.80 | -23.98 | -18.04 | -12.91 | -16.18 |
| Weighted avg. shares (diluted) | 46.71M | 30.11M | 946,000 | 946,000 | 946,000 | 946,000 |
| Balance sheet | ||||||
| Cash & equivalents | $239.15M | $237.37M | $49.86M | — | — | — |
| Short-term investments | $191.09M | $220.09M | $113.67M | — | — | — |
| Current assets | $438.16M | $464.00M | $169.43M | — | — | — |
| PP&E, net | $555,000 | $596,000 | $648,000 | — | — | — |
| Total assets | $442.71M | $467.78M | $175.26M | — | — | — |
| Current liabilities | $12.94M | $12.94M | $13.19M | — | — | — |
| Total liabilities | $13.44M | $13.51M | $13.71M | — | — | — |
| Shareholders' equity | $429.27M | $454.27M | -$198.62M | -$158.00M | -$141.47M | -$129.15M |
| Cash flow statement | ||||||
| Operating cash flow | -$28.29M | -$22.64M | -$21.58M | -$16.39M | -$15.33M | -$13.03M |
| Capital expenditure | $34,000 | $23,000 | $112,000 | $0 | $0 | $16,000 |
| Free cash flow | -$28.32M | -$22.66M | -$21.70M | -$16.39M | -$15.33M | -$13.05M |
| Investing cash flow | $30.10M | -$107.44M | -$15.85M | $0 | $21.50M | -$5.99M |
| Financing cash flow | $47,000 | $317.58M | -$460,000 | -$30,000 | -$30,000 | -$29,000 |
| Depreciation & amortization | $75,000 | $75,000 | $73,000 | $76,000 | $77,000 | $75,000 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.